Altimmune names Richard Menziuso VP, Global Controller and Principal Accounting Officer, effective Sept 29

Altimmune, Inc.

Richard Menziuso, 51, appointed Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026; CFO Gregory Weaver remains in his role.
Menziuso was VP, Corporate Controller at Centessa Pharmaceuticals from 2021 until its 2026 acquisition by Eli Lilly; before that North America Controller at Thermo Fisher (2019-2021).
Earlier roles: VP, Accounting and Controller at Axovant Gene Therapies (2017-2019) and finance positions at LifeCell, ConvaTec, Tyco, PricewaterhouseCoopers and Bristol-Myers Squibb.
He brings 28 years of finance and accounting experience, including 12 in public accounting, and holds a B.B.A. from Pace University; he is a CPA and Chartered Global Management Accountant.
Company will enter an indemnification agreement with Menziuso mirroring those for other executive officers; no family relationships or Item 404(a) related-party transactions disclosed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.